Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 90100 in Extensive Psoriasis Vulgaris
NCT01600222Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of calcipotriol + betamethasone in Psoriasis vulgaris (PV), sponsored by LEO Pharma. Primary endpoints: Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge, Change in Albumin-corrected Serum Calcium From Baseline to Day 28 and 2 more. Started May 2012; status: completed.
02
Drugs
calcipotriol + betamethasone
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT01600222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01600222.